Shiqiang Qu

832 total citations
45 papers, 365 citations indexed

About

Shiqiang Qu is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Shiqiang Qu has authored 45 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Hematology, 30 papers in Genetics and 14 papers in Rheumatology. Recurrent topics in Shiqiang Qu's work include Acute Myeloid Leukemia Research (28 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (28 papers) and Eosinophilic Disorders and Syndromes (13 papers). Shiqiang Qu is often cited by papers focused on Acute Myeloid Leukemia Research (28 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (28 papers) and Eosinophilic Disorders and Syndromes (13 papers). Shiqiang Qu collaborates with scholars based in China, United Kingdom and United States. Shiqiang Qu's co-authors include Tiejun Qin, Zefeng Xu, Lijuan Pan, Robert Peter Gale, Bing Li, Zhijian Xiao, Naibo Hu, Gang Huang, Liwei Fang and Yue Zhang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Haematology.

In The Last Decade

Shiqiang Qu

38 papers receiving 357 citations

Peers

Shiqiang Qu
Liwei Fang China
Tiejun Qin China
Xiaosha Zhang United States
Nanna Sulai United States
Mridul Agrawal United States
Guntram Buesche Germany
Barbara Rocca Italy
Laurence Baranger France
Marilena Caresana Italy
Michael Heinsch Germany
Liwei Fang China
Shiqiang Qu
Citations per year, relative to Shiqiang Qu Shiqiang Qu (= 1×) peers Liwei Fang

Countries citing papers authored by Shiqiang Qu

Since Specialization
Citations

This map shows the geographic impact of Shiqiang Qu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shiqiang Qu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shiqiang Qu more than expected).

Fields of papers citing papers by Shiqiang Qu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shiqiang Qu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shiqiang Qu. The network helps show where Shiqiang Qu may publish in the future.

Co-authorship network of co-authors of Shiqiang Qu

This figure shows the co-authorship network connecting the top 25 collaborators of Shiqiang Qu. A scholar is included among the top collaborators of Shiqiang Qu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shiqiang Qu. Shiqiang Qu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Qin, Tiejun, Shiqiang Qu, Lijuan Pan, et al.. (2024). Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis. Leukemia. 38(6). 1334–1341. 4 indexed citations
3.
Liu, Jinqin, Yingying Zhao, Peihong Zhang, et al.. (2023). ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms.. PubMed. 108(5). 1359–1373. 4 indexed citations
4.
Zhang, Yudi, Tiejun Qin, Zefeng Xu, et al.. (2022). Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms. Leukemia. 36(12). 2875–2882. 23 indexed citations
5.
Zhang, Yudi, Tiejun Qin, Zefeng Xu, et al.. (2022). IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes. Experimental Hematology and Oncology. 11(1). 73–73. 22 indexed citations
6.
Liu, Jinqin, Yingying Zhao, Lin Yang, et al.. (2022). <i>ASXL1</i> mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms. Haematologica. 108(5). 1359–1373. 10 indexed citations
7.
Qu, Shiqiang, Donglei Zhang, Zefeng Xu, et al.. (2022). ASXL2 mutated myelodysplastic syndrome in a novel germline G6b variant. Leukemia Research Reports. 17. 100303–100303. 1 indexed citations
8.
9.
Qu, Shiqiang, Zefeng Xu, Tiejun Qin, et al.. (2022). Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study. Hematological Oncology. 40(4). 787–795. 4 indexed citations
10.
Liu, Dan, Bing Li, Zefeng Xu, et al.. (2021). RBC distribution width predicts thrombosis risk in polycythemia vera. Leukemia. 36(2). 566–568. 10 indexed citations
11.
Qin, Tiejun, Zefeng Xu, Huijun Huang, et al.. (2020). [Mean corpuscular volume ≤100 fl was an independent prognostic factor in patients with myelodysplastic syndrome and bone marrow blast<5 percent].. PubMed Central. 41(1). 28–33. 1 indexed citations
12.
Cui, Yajuan, Hongyan Tong, Xin Du, et al.. (2016). TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia. PubMed. 3. 50–50. 9 indexed citations
13.
Cui, Yajuan, Hongyan Tong, Xin Du, et al.. (2015). Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. Experimental Hematology and Oncology. 4(1). 14–14. 29 indexed citations
14.
Gale, Robert Peter, Wen Cui, Gang Huang, et al.. (2015). A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Experimental Hematology and Oncology. 5(1). 12–12. 18 indexed citations
15.
Wang, Jingya, Tiejun Qin, Zefeng Xu, et al.. (2015). [Long- term outcome of thalidomide and cyclosporine in patients with IPSS low/intermediate- 1 myelodysplastic syndromes].. PubMed. 36(11). 942–6. 1 indexed citations
16.
Wang, Jingya, Robert Peter Gale, Zefeng Xu, et al.. (2014). Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis. Leukemia Research. 38(10). 1207–1211. 6 indexed citations
17.
Cui, Rui, Robert Peter Gale, Zefeng Xu, et al.. (2014). Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Leukemia Research. 38(5). 545–550. 40 indexed citations
18.
Wang, Jingya, Robert Peter Gale, Zefeng Xu, et al.. (2014). Prognostic Impact of Splenomegaly on Survival of Chinese with Primary Myelofibrosis. Blood. 124(21). 3210–3210.
19.
Xu, Zefeng, Robert Peter Gale, Yue Zhang, et al.. (2012). Unique features of primary myelofibrosis in Chinese. Blood. 119(11). 2469–2473. 22 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liwei Fang Breakdown of academic impact, for papers by Tiejun Qin Breakdown of academic impact, for papers by Xiaosha Zhang Breakdown of academic impact, for papers by Nanna Sulai Breakdown of academic impact, for papers by Mridul Agrawal Breakdown of academic impact, for papers by Guntram Buesche Breakdown of academic impact, for papers by Barbara Rocca Breakdown of academic impact, for papers by Laurence Baranger Breakdown of academic impact, for papers by Marilena Caresana Breakdown of academic impact, for papers by Michael Heinsch
Rankless by CCL
2026